Metabolic Changes in Prostate Cancer Patients With Androgen-ablation Therapy (AAT)

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT01284608

Acronym

UROCOR

Enrollment

197

Registered

2011-01-27

Start date

2011-03-31

Completion date

2012-12-31

Last updated

2012-12-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Prostatic Cancer

Keywords

Observational, prospective, metabolic changes, metabolic syndrome, diabetes, prostatic cancer, risk fracture

Brief summary

This is an observational, prospective, non-interventional and multi-centre study, to assess the impact of androgen ablation therapy in blood triglycerides, cholesterol and glucose, body fat distribution and fracture risk to ten years using FRAX model in patients with prostate cancer. The patients will be following for 12 months

Interventions

None listed

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

MALE

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* Prostate cancer patient requiring androgen-ablation treatment: LHRH analogs, surgical castration, antiandrogen treatment * Provision of informed consent prior to conducting any study-related procedure

Exclusion criteria

* Patient involved in a Clinical Trial

Design outcomes

Primary

Measure	Time frame
Metabolic syndrome	3 months
Diabetes	3 months

Secondary

Measure	Time frame
Fracture Risk Assessment Tool (FRAx) assessment	0 and 12 months

Countries

Spain

Outcome results